Introduction

Migration of encephalitogenic CD4 + T cells to the central nervous system (CNS) induces
relapsing experimental autoimmune encephalomyelitis (R-EAE), a disease model of multiple sclerosis (MS) characterized by inflammation and demyelination of the CNS 1 . Active immunization of SJL mice with the immunodominant epitope of proteolipid protein, PLP139-151, induces a moderate to severe acute paralytic phase of R-EAE followed by remission and subsequent relapses 2 . Relapses are mediated by epitope spreading, a process in which T cells respond against endogenous myelin peptides recruited secondary to acute CNS damage 3, 4 .
Tolerization with the PLP178-191 peptide during remission from acute PLP139-151-induced R-EAE inhibits development of clinical relapses confirming the predominant pathologic role of PLP178-191-specific T cells in disease progression 3, 5, 6 . Elucidation of the mechanisms by which activated T cells cross the blood-brain barrier and gain entry to the CNS is of significant importance to the pathogenesis of R-EAE and MS.
The integrin 4 1, also known as the very late activation antigen-4 (VLA-4), has been shown to play an integral part in the CNS homing of cells that induce disease [7] [8] [9] [10] . Interaction of VLA-4 with its ligand, vascular cell adhesion molecule (VCAM-1), which is expressed on CNS endothelium, allows entry of encephalitogenic T cells into the CNS 7 . Interfering with this interaction is postulated to have a potential beneficial therapeutic effect for many autoimmune diseases, including MS.
In addition to its role in T cell entry into the CNS, VLA-4 likely plays an important role in other immune functions. For example, VLA-4 may act as a costimulatory molecule on T cells and could therefore influence T cell activation and differentiation [11] [12] [13] [14] . Potential costimulatory activities could explain the results observed in our previous study in which treatment with an anti-VLA-4 monoclonal antibody (mAb) initiated during ongoing disease increased disease relapses and accumulation of CD4 + T cells in the CNS 15 . Most significantly, treatment with anti-VLA-4 either prior to or during ongoing R-EAE enhanced Th1 responses to both the priming peptide and to endogenous myelin epitopes released secondary to acute tissue damage (i.e., For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From epitope spreading). These results suggest that treatment with anti-VLA-4 mAb has multiple effects on the immune system. Despite the enhanced clinical EAE observed when mice with pre-existing disease were treated with anti-VLA-4, small molecule VLA-4 antagonists that block homing of activated T cells without triggering costimulatory or other potential effector activities remain as promising therapeutics for treatment of autoimmune diseases.
Considering the complex role of VLA-4 in immune responses and to obviate the potential delivery of agonistic T cell costimulatory signals by bivalent anti-VLA-4 mAbs, we examined the effects of long-term treatment with the small molecule VLA-4 antagonist, BIO 5192, begun either prior to or after the appearance of clinical symptoms in active R -EAE. In this study, 21 daily treatments of BIO 5192 were administered pre-clinically, at the peak of acute disease, or during the first disease remission. The subsequent effect on disease course was determined.
Although preclinical administration of anti-VLA-4 delayed R-EAE induction, 50% of animals began to exhibit clinical signs of EAE while on treatment and 80% experienced a striking posttreatment disease exacerbation five days after termination of treatment. Treatment initiated during disease remission moderately enhanced disease of mice on drug and post-treatment disease exacerbation was again observed. In contrast, the relapse rate was significantly lowered in mice in which treatment was initiated at the peak of acute disease while the animals remained on drug despite the fact that the mice exhibited augmented peripheral myelin peptidespecific Th1 responses. However, following cessation of treatment, encephalitogenic cells were released from peripheral lymphoid compartments again resulting in a striking post-treatment disease exacerbation characterized by increased infiltration of CD4 + T cells into the CNS.
For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From Clinical Evaluation. Clinical severity was assessed on a 0 to 5 scale as follows: grade 0, no abnormality; grade 1, limp tail or hind limb weakness; grade 2, limp tail and hind limb weakness (waddling gait); grade 3, partial hind limb paralysis; grade 4, complete hind limb paralysis; and grade 5, moribund. A relapse was defined as a sustained increase (greater than two days) of at least one full grade in clinical score after the animal had previously improved at least a full clinical score and had stabilized for at least two days. The data are plotted as the mean clinical score for all animals in a particular treatment group or as the relapse rate (total number of relapses in a group during the observation period divided by the total number of mice in that group). Mean peak clinical score is defined as the greatest clinical score reached during the specified phase of disease/treatment. The severity index was calculated by adding the clinical scores for each mouse over a specified time period and dividing this number by the number of scores examined.
Preparation of tissue for immunohistochemistry.
At days 39 and 44 post-priming (for mice in which treatment was initiated at the peak of acute disease phase and treated for 22 days), two mice per time point were perfused with PBS and fresh 4% paraformaldehyde (Sigma). Spinal cords and brains were dissected out and blocks of tissue were flash frozen in O.C.T. compound (Miles Laboratories, Elkart, Indiana) with liquid nitrogen. Tissue from the lower thoracic region of the spinal cord was sectioned at 6µm on a Reichert-Jung 1800 cryotome (Leica Instruments, Deerfield, Illinois) and mounted on Superfrost Plus electrostatically charged slides.
Immunohistochemistry. Slides were stained using Tyramide Signal Amplification (TSA) Direct Kit (NEN Life Science Products, Boston, Massachusetts) according to the manufacturer's protocol. Tissue was thawed, air dried and re-hydrated in PBS. After catalyzing endogenous peroxidases in 0.3% hydrogen peroxide, non-specific staining was blocked using an avidin/biotin blocking kit (Vector Labs, Burlingame, CA) in addition to the blocking reagent provided by the TSA kit. For CD4, CD8, B220 and VCAM-1 staining, slides were incubated with biotinylated anti-L3T4, anti-Ly-2, RA3-6B2, and 429 (MVCAM.A) (PharMingen, San Diego, CA), For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From respectively, for 1 h at room temperature. Sections were counterstained with 0.1 µg/ml DAPI (Sigma) and coverslipped with Vectashield mounting medium (Vector). Tissue was examined by epifluorescence using a chroma triple-band filter (Chroma Technology Corporation, Brattleboro, Vermont).
Isolation of mRNA, first strand cDNA synthesis and RT-PCR. At day 39 and day 44 post priming (for mice treated for 22 days beginning at the acute phase ), five mice per group were anesthetized and perfused through the left ventricle with 30 ml of PBS. Spinal cords were extruded by flushing the vertebral canal with PBS and then rinsed in PBS. Tissues were forced through a 100-mesh stainless steel screen to give a single cell suspension and pelleted by centrifugation (500 × g) for 5 min at 4°C. The pellets were resuspended vigorously in 16 ml 4 M guanidinium isothiocyanate/50 mM Tris-Cl (pH 7.5)/25 mM EDTA (Life Technologies, Gaithersburg, MD), and 1% 2-ME and 0.5% N-lauroylsarcosine (Sigma-Aldrich, St. Louis, MO).
Shearing of DNA was facilitated by repeatedly forcing the resulting suspension through a 23-gauge needle. Total RNA was isolated by high-speed gradient centrifugation (27,000 rpm) of 8 ml lysate through a 3 ml 5.7 M CsCl pad using a SW41 swinging bucket rotor for 20 h at 4°C. Furthermore, the 15-day post-treatment severity index of 1.40 was significantly greater (p < 0.05) in BIO 5192-treated animals than the index of 0.57 in vehicle-treated animals ( Table 1) .
Following the post-treatment exacerbation, 5/10 of the animals that had received the smallmolecule antagonist compared to 2/9 control animals entered into a chronic phase of R-EAE.
BIO 5192 treatment initiated during disease remission moderately enhances
clinical signs of R-EAE while on treatment and also results in post-treatment exacerbation. When treatment was initiated during disease remission, animals in the vehicle and BIO 5192 treated group had a similar mean day of disease onset and disease incidence ( Figure 1B ). While on treatment, clinical disease parameters were not affected compared to controls until day 15, when disease in BIO 5192-treated mice worsened somewhat. However, when treatment ended, the BIO 5192 group displayed a synchronous exacerbation of disease.
As seen in Table 1 Treatment initiation at the peak of the acute phase accelerates entrance into disease remission, inhibits relapses while on treatment, but results in a post-treatment exacerbation. BIO 5192 was also administered at the peak of the acute phase and the resultant effects on R-EAE were monitored. It is important to note that animals in the vehicletreated group had similar mean day of onset of R-EAE (12.6 in the vehicle group vs. 13.0 in the BIO 5192 group), incidence (9/9), and severity compared to the BIO 5192 treated group before the start of treatment. In contrast to initiation of treatment in remission, disease relapses were inhibited when BIO 5192 was administered at the peak of the acute phase ( Figure 1C Due to the severe exacerbation observed after removal of BIO 5192, we compared the ability of short-term treatment (22 daily treatments) vs. long-term drug treatment (44 daily treatments) beginning at the peak of acute phase to maintain disease regulation. Once again, the onset of disease remission was accelerated in the BIO 5192-treated animals ( Figure 2 ).
After four treatments, the BIO 5192-treated groups had a mean clinical score of 0.56 compared to a mean clinical score of 0.93 for the vehicle control group (p<0.05). However, beginning around day 15 post-treatment initiation (PTI) BIO 5192-treated groups started to exhibit slightly increased disease severity. This trend continued to a point around day 20 PTI where no inhibition of disease was seen and the mean clinical scores of treated and control groups were equal ( Figure 2 ). This confirms the results seen in Figure 1 . However, as shown in Table 2 , while the mice were on treatment, both the relapse rate and the severity index were significantly (Table 2) . A similar pattern was observed when mice receiving the 44-day regimen were removed from BIO 5192 treatment. These animals exhibited post-treatment exacerbation that peaked at a mean clinical score of 2.0 six days after treatment ceased as compared to the vehicle control group which had a mean clinical score of only 0.80 (Figure 2 ).
The mean peak clinical scores, the severity indices, and relapse rates were all significantly higher in the BIO 5192 vs. vehicle control groups (p < 0.05) after treatment cessation, regardless of whether the animals had been treated for 22 or 44 days (Table 2) . Thus, reduced relapses were observed as long as BIO 5192 treatment continued, but a severe relapse occurred shortly after treatment was discontinued.
Acute phase initiation of treatment with BIO 5192 enhances proliferation and IFNsecretion in response to the priming epitope and augments epitope spreading. PLP139-151-specific proliferative responses ( Figure 3A) and IFN-secretion ( Figure 3B ) of splenic T cells taken on day 22 PTI (day 39 post-priming) were elevated upon stimulation with a range of doses of the priming peptide in mice which had received BIO 5192 initiated at the peak of the acute disease ( Figure 2 ). In addition, 48 h IL-2 secretion was also substantially elevated and enhanced proliferative responses in the lymph nodes were also observed at this time (data not shown). Proliferation of splenic T cells to the primary relapse-associated PLP178-191 epitope 5, 6 was slightly higher in the BIO 5192-treated animals ( Figure 3C ). More significantly, secretion of IFN-at 72 h to PLP178-191 and to MBP84-104, a second epitope often associated with disease relapse, was also substantially higher in BIO 5192-treated animals ( Figure 3D . Disease was followed long-term and post-treatment disease exacerbation was observed, but slight compared to what we observed in the SJL relapsingremitting EAE model. The differences in these results may be due to the relapsing nature of the SJL model which involves epitope spreading 3, 4 , or to species differences in disease mechanism.
One possible mechanism for the profound disease exacerbation we noted is a proposed role for VLA-4 in T cell costimulation [11] [12] [13] [14] . In fact, we demonstrated that the addition of anti-CD49d to anti-CD3/anti-CD28 coated polystyrene beads induced significantly greater proliferation 15 For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From 
